Novartis agrees to acquire UK biotech Myricx Bio for up to $1.5 billion.
Swiss pharmaceutical company Novartis announced an agreement to acquire UK-based biotechnology firm Myricx Bio. The deal is valued at up to $1.5 billion and is expected to close in the second half of 2026.
3
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Financial Times
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Both outlets report identical deal terms; Financial Times leads with the headline figure while Reuters clarifies the up to contingency structure.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Novartis to acquire UK-based Myricx Bio for up to $1.5 billion”
“Novartis to buy UK biotech Myricx Bio in $1.5bn deal”
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed